(Total Views: 262)
Posted On: 01/26/2024 4:56:57 PM
Post# of 90
NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals Living with ASD
PaxMedica (NASDAQ: PXMD) recently released an insightful video detailing the outcomes of its Phase 2 study on autism spectrum disorder (“ASD”), initially published in the Annals of General Psychiatry. “This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD… Focused on evaluating the efficacy and safety of suramin intravenous infusions, the study’s 10 mg/kg suramin arm displayed promising results in improving core symptoms of ASD, showcasing statistically significant improvements in the Clinical Global Impressions-Improvement (‘CGI-I’) scale compared to the placebo group,” a recent article explains. “PaxMedica’s unwavering commitment to pioneering research in neurological disorders is highlighted in the video release, demonstrating the company’s dedication to enhancing the quality of life for individuals living with ASD.”
For more information about the company, visit www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
PaxMedica (NASDAQ: PXMD) recently released an insightful video detailing the outcomes of its Phase 2 study on autism spectrum disorder (“ASD”), initially published in the Annals of General Psychiatry. “This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD… Focused on evaluating the efficacy and safety of suramin intravenous infusions, the study’s 10 mg/kg suramin arm displayed promising results in improving core symptoms of ASD, showcasing statistically significant improvements in the Clinical Global Impressions-Improvement (‘CGI-I’) scale compared to the placebo group,” a recent article explains. “PaxMedica’s unwavering commitment to pioneering research in neurological disorders is highlighted in the video release, demonstrating the company’s dedication to enhancing the quality of life for individuals living with ASD.”
For more information about the company, visit www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
